Statistics from Altmetric.com
Implications for practice and research
The risk of arterial thrombosis (AT) is very low in all oral contraceptive pills (OCPs)
Risks of venous thromboembolism (VTE) vary according to the progestin type
Drospirenone OCPs confer a higher risk of VTE than levonorgestrel OCPs
That OCPs increase the risk of venous and arterial thrombosis has been well recognised and well researched since OCPs were first marketed. Since the earliest reporting of the high risk of VTE (deep vein thrombosis and pulmonary embolism) in OCP users, the doses and formulations of both the oestrogen and progestin components of OCPs have changed, initially resulting in a decrease in the risk of thrombotic events, and later leading to differences in risk between OCPs. However, the following questions remain: what are the risks of thrombotic …
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.